Cargando…

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

BACKGROUND: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose (RP2D). METHODS: Patients with advanced solid tumours received ARQ 087 administ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadopoulos, K P, El-Rayes, B F, Tolcher, A W, Patnaik, A, Rasco, D W, Harvey, R D, LoRusso, P M, Sachdev, J C, Abbadessa, G, Savage, R E, Hall, T, Schwartz, B, Wang, Y, Kazakin, J, Shaib, W L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729432/ https://www.ncbi.nlm.nih.gov/pubmed/28972963 http://dx.doi.org/10.1038/bjc.2017.330

Ejemplares similares

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
por: Hall, Terence G., et al.
Publicado: (2016)

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
por: Biesecker, Leslie G., et al.
Publicado: (2020)

Transmission of the atypical/Nor98 scrapie agent to Suffolk sheep with VRQ/ARQ, ARQ/ARQ, and ARQ/ARR genotypes
por: Cassmann, Eric D., et al.
Publicado: (2021)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015)

In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
por: Patnaik, A., et al.
Publicado: (2016)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

ARQ20 : arquitectura en la España del siglo XX /
Publicado: (2006)

ARQ20 : arquitectura en la España del siglo XX.
Publicado: (2012)

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018)

Macintosh in the laboratory (CERN-PRE-87-087)
por: Taylor, B G
Publicado: (1987)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2017)

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
por: Ranieri, C., et al.
Publicado: (2018)

Transmission of atypical scrapie to homozygous ARQ sheep
por: OKADA, Hiroyuki, et al.
Publicado: (2016)

Analysis of channel uncertainty in ARQ relay networks
por: Ajmal, Hina, et al.
Publicado: (2018)

Index Coded Automatic Repeat Request (ARQ)
por: Choi, Sang Won
Publicado: (2020)

AB087. The biotherapy for bladder cancer
por: Wang, Zhiping
Publicado: (2015)

Feinix-Arq: distribución GNU/LINUX a medida para la Facultad de Arquitectura de la Universidad Veracruzana /
por: Martínez Tovar, Víctor Daniel
Publicado: (2007)

Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
por: Lindhurst, Marjorie J., et al.
Publicado: (2015)

Strain Typing of Classical Scrapie and Bovine Spongiform Encephalopathy (BSE) by Using Ovine PrP (ARQ/ARQ) Overexpressing Transgenic Mice
por: Fatola, Olanrewaju I., et al.
Publicado: (2022)

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
por: Tolcher, Anthony W., et al.
Publicado: (2013)

Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
por: Nandan, Devki, et al.
Publicado: (2018)

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
por: Soncini, Debora, et al.
Publicado: (2019)

Location Distribution of 2,087 Osteochondral Lesions of the Talus
por: van Diepen, Pascal R., et al.
Publicado: (2020)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Hybrid ARQ Scheme with Autonomous Retransmission for Multicasting in Wireless Sensor Networks
por: Jung, Young-Ho, et al.
Publicado: (2017)

ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

MON-087 Natural History and Neurodevelopmental Outcomes in Perinatal Stress Induced Hyperinsulinism
por: Sigal, Winnie M, et al.
Publicado: (2020)

MAC Performance Analysis for Reliable Power-Line Communication Networks with ARQ Scheme
por: Hao, Sheng, et al.
Publicado: (2020)

Psychometric properties of the Adolescent Resilience Questionnaire (ARQ) in a sample of Swedish adolescents
por: Nilsson, Doris, et al.
Publicado: (2022)

P087 Impact of COVID-19 on mental health of children with cystic fibrosis and their parents
por: Bhatnagar, R., et al.
Publicado: (2021)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fko6uqvnofhhhskmvh77jpdvo2